Table 4. Univariate and Multivariate OR and 95% CI for Association of Postoperative Recurrence.
| Absence (n = 86) | Recurrence (n = 35) | Univariate OR (95% CI) | P-value | Multivariate OR (95% CI)† | P-value | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| < 75 | 58 | 20 | 1 | 1 | ||
| ≥ 75 | 28 | 15 | 1.55 (0.69 - 3.48) | 0.285 | 1.78 (0.70 - 4.53) | 0.225 |
| Sex | ||||||
| Female | 31 | 9 | 1 | 1 | ||
| Male | 55 | 26 | 1.63 (0.68 - 3.91) | 0.276 | 2.19 (0.80 - 5.98) | 0.126 |
| Stage | ||||||
| Stage I-II | 59 | 15 | 1 | 1 | ||
| Stage III | 24 | 20 | 3.28 (1.44 - 7.45) | 0.005 | 2.20 (0.86 - 5.66) | 0.100 |
| Failure: 3 | ||||||
| Disease | ||||||
| Colorectal cancer | 58 | 24 | 1 | |||
| Stomach cancer | 28 | 11 | 0.95 (0.41 - 2.21) | 0.904 | ||
| Charlson comorbidity index (points) | ||||||
| ≤ 2 | 79 | 30 | 1 | |||
| > 3 | 7 | 5 | 1.88 (0.55 - 6.39) | 0.311 | ||
| Histological type | ||||||
| Undifferentiated | 8 | 3 | 1 | |||
| Differentiated | 78 | 32 | 1.09 (0.27 - 4.39) | 0.899 | ||
| CEA (ng/mL) | ||||||
| < 6 | 53 | 18 | 1 | |||
| ≥ 6 | 30 | 16 | 1.57 (0.70 - 3.53) | 0.274 | ||
| Failure: 4 | ||||||
| CA19-9 (U/mL) | ||||||
| < 37 | 73 | 25 | 1 | |||
| ≥ 37 | 8 | 7 | 2.56 (0.84 - 7.77) | 0.098 | ||
| Failure: 8 | ||||||
| CRP (mg/dL) | ||||||
| < 0.2 | 36 | 13 | 1 | |||
| ≥ 0.2 | 38 | 17 | 1.24 (0.53 - 2.91) | 0.623 | ||
| Failure: 17 | ||||||
| Albumin (g/dL) | ||||||
| ≥ 3.5 | 50 | 19 | 1 | |||
| < 3.5 | 24 | 12 | 1.32 (0.55 - 3.15) | 0.537 | ||
| Failure: 16 | ||||||
| Hemoglobin (g/dL) | ||||||
| ≥ male 11; female 10 | 53 | 24 | 1 | |||
| < male 11; female 10 | 24 | 6 | 0.55 (0.20 - 1.53) | 0.252 | ||
| Failure: 14 | ||||||
| HbA1c (%) | ||||||
| < 6.5 | 54 | 20 | 1 | |||
| ≥ 6.5 | 12 | 6 | 1.35 (0.45 - 4.08) | 0.595 | ||
| Failure: 29 | ||||||
| PNI (points) | ||||||
| ≥ 40 | 55 | 25 | 1 | |||
| < 40 | 15 | 5 | 0.73 (0.24 - 2.24) | 0.586 | ||
| Failure: 21 | ||||||
| BMI (kg/m2) | ||||||
| 18.5 - 24.9 | 56 | 25 | 1 | |||
| < 18.5 | 17 | 5 | 0.66 (0.22 - 1.99) | 0.459 | ||
| ≥ 25 | 13 | 5 | 0.86 (0.28 - 2.68) | 0.797 | ||
| P for trend 0.686 | ||||||
| SMI (kg/m2) | ||||||
| ≥ male 6.25; female 5.17 | 65 | 27 | 1 | |||
| < male 6.25; female 5.17 | 21 | 8 | 0.92 (0.36 - 2.32) | 0.855 | ||
| VFA (cm2) | ||||||
| ≥ 100 cm2 | 38 | 18 | 1 | |||
| < 100 cm2 | 44 | 16 | 0.77 (0.35 - 1.71) | 0.518 | ||
| Failure: 5 | ||||||
| Body fat (%) | ||||||
| ≥ male 30; female 42 | 11 | 3 | 1 | |||
| < male 30; female 42 | 75 | 32 | 1.56 (0.41 - 5.98) | 0.514 | ||
| Treatment technique | ||||||
| Laparoscopic | 19 | 3 | 1 | |||
| Laparotomy | 67 | 32 | 3.03 (0.83 - 10.97) | 0.092 | ||
| Chemotherapy | ||||||
| Absence | 64 | 13 | 1 | 1 | ||
| Prescription | 22 | 22 | 4.92 (2.13 - 11.40) | < 0.001 | 3.77 (1.50 - 9.49) | 0.005 |
PNI: prognostic nutritional index; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; CRP: C-reactive protein; VFA: visceral fat area; BMI: body mass index; SMI: skeletal muscle mass index. †Model included age, sex, stage and chemotherapy.